Navicure is looking to acquire Zirmed Inc
With financial backing from Bain Capital, cloud-based healthcare solution company Navicure is set to potentially acquire Zirmed Inc. Navicure works to enable healthcare organisations increase revenue, accelerate cash flow, and reduce the cost and effort of managing claims, patient billing and payments, and healthcare data analytics across the US.
If the deal goes through, Navicure could be valued at approximately $750 million, Reuters reports. In March, the company appointed a new Chief Growth Officer Kermit Randa, who will support Navicure’s continued revenue and profitability.
“Growth is at the center of our corporate strategy. The creation of the Chief Growth Officer role illustrates our deep commitment to our clients and our partners,” explained Jim Denny, co-founder, president and CEO of Navicure.
- How Philips has gone from electronics to transforming healthcare
- Centene enters New York in a new $3.85BN agreement with Fidelis Care
- Teva lands a new Chief Executive
Such acquisitions highlight the growing interest in tech-health, with companies viewing the industry’s long-term growth, which is sent to rapidly rise, with new products and technologies placed within acute settings, such as hospitals and community clinics.
At present, Zirmed supports the IT infrastructure within hospitals, providing the required software and supporting all aspects of revenue cycle management. In order to further streamline its services, the company reduced its staff numbers across its three locations – Chicago, Louisville and Culver City but is seeing continued growth.
Zirmed was even received the top spot on Louisville Business First’s list of the areas largest information technology services companies.
NHS opens 8 clinical trial sites to assess cancer treatment
The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy.
The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment. They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities.
Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.
OncoHost, an oncology startup, will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®.
“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.
“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient."
"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”
Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.